Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €29.28 EUR
Change Today +0.316 / 1.09%
Volume 70.0
ZA7 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:20 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

zafgen inc (ZA7) Snapshot

Open
€29.13
Previous Close
€28.96
Day High
€29.28
Day Low
€29.13
52 Week High
03/20/15 - €48.06
52 Week Low
08/4/14 - €12.86
Market Cap
787.4M
Average Volume 10 Days
51.3
EPS TTM
--
Shares Outstanding
26.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZAFGEN INC (ZA7)

Related News

No related news articles were found.

zafgen inc (ZA7) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZA7) Details

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studies to reduce the severity of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and abdominal obesity. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

26 Employees
Last Reported Date: 05/14/15
Founded in 2005

zafgen inc (ZA7) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $425.0K
President
Total Annual Compensation: $195.4K
Chief Financial Officer
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Chief Commercial Officer
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

zafgen inc (ZA7) Key Developments

Zafgen, Inc. Announces Executive Appointments

Zafgen, Inc. announced the appointments of Nerissa Kreher, M.D., M.S., M.B.A., as Global Head of Medical Affairs, and Kevin P. Malobisky, Ph.D., M.S., R.A.C., as Global Head of Regulatory. Most recently, Dr. Kreher was the Global Clinical Development Lead, Neonatology, at Shire. Previously, she held several roles at Alexion Pharmaceuticals and Enobia Pharma, where she became the Executive Medical Director, Medical Affairs Franchise Lead, Metabolic Diseases, and was responsible for the global medical affairs metabolic disease program. Most recently, Dr. Malobisky was a Senior Regulatory Consultant working with the Harte Group. Prior to that, he spent 14 years with Sanofi, where he held positions of increasing seniority in Regulatory Affairs and ultimately served as Associate Vice President, Global Regulatory Affairs, a position comprised of two roles: Regional Head, United States and Canada, and Global Head, Fibrosis & Cardiovascular.

Zafgen, Inc. Presents at UBS Global Healthcare Conference, May-18-2015

Zafgen, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States.

Zafgen, Inc. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Zafgen, Inc. announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $13,240 compared with $4,521 for the same period a year ago. Net loss attributable to common stockholders was $13,472 or $0.53 per basic and diluted share compared with $4,507 or $6.18 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZA7:GR €29.28 EUR +0.316

ZA7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZA7.
View Industry Companies
 

Industry Analysis

ZA7

Industry Average

Valuation ZA7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.